Draft:Sten Ohlson
| Submission declined on 15 January 2025 by SafariScribe (talk). This submission's references do not show that the subject qualifies for a Wikipedia article—that is, they do not show significant coverage (not just passing mentions) about the subject in published, reliable, secondary sources that are independent of the subject (see the guidelines on the notability of people). Before any resubmission, additional references meeting these criteria should be added (see technical help and learn about mistakes to avoid when addressing this issue). If no additional references exist, the subject is not suitable for Wikipedia.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
|  |
Sten Ohlson | |
|---|---|
| Born | Sten Ohlson December 24, 1950 Stockholm |
| Nationality | Swedish |
| Scientific career | |
| Fields | Biochemistry and Biotechnology |
Sten Ohlson (born 24 December 1950 in Stockholm, Sweden) is a biochemist and bioentrepreneur. He is a professor of applied biochemistry and biotechnology currently working at Linköping University, Linköping , Sweden as a visiting professor. He is renowned for his pioneering contributions in cell culture technology and engineering, analytical biochemistry, continuous biosensors, clinical diagnostics and drug discovery. He is also a bioentrepreneur and has co-founded four life-science companies (Perstorp Biolytica AB, ProLiff AB, KalBiotech AB and Transientic Interactions AB).
Education
[edit]After graduating from Whitlockska Samskolan in Stockholm in 1969, he moved to Lund, Sweden for university studies where he received in 1975 a MSc in chemical engineering at faculty of engineering (Lund Institute of Technology) at Lund University, Lund, Sweden followed up in 1981 by a PhD in biochemical engineering at Lund University under the supervisors of Klaus Mosbach and Per-Olof Larsson. The title of his thesis was ¨ Part I: Immobilized whole-cell catalysts applied to steroid conversions and denitrification of water. Part II: HPLAC (High Performance Liquid Affinity Chromatography).[1] In 1989, he was awarded the title of docent by the Faculty of Engineering at Lund University.
Career
[edit]After finishing his doctorate studies, Ohlson went to industrial positions for thirteen years (1980–1993). First, he was a research manager at the department of Extracorporeal Immunotherapy at Gambro AB in Lund, Sweden (1980–1984) leading as a principal investigator therapeutic procedures to remove harmful substances from blood/plasma.[2] In 1984, he co-founded Perstorp Biolytica AB as one of the first biotechnology companies in the science park of Ideon in Lund, Sweden where he was leading the developments of bioseparation technologies using HPLC and hollow fiber membranes as well as producing substances for immunoseparations. After Perstorp Biolytica AB was acquired by HyClone Laboratories Inc.,[3] Logan, Utah, USA. In 1990, Ohlson moved to HyClone as a manager for R&D and marketing in animal cell culture and bioanalytical monitoring.
In 1993, Ohlson decided to go back to academia by becoming an associate professor and head of the biotechnology group of University of Kalmar, Kalmar, Sweden. In 1999 he was appointed a full professor in applied biochemistry at the University of Kalmar which later in 2010 merged with Växjö University to form Linnaeus University.[4] Concomitantly, Ohlson also had from 2012 to 2014 the Lee Wee Nam visiting professorship at the Nanyang Technological University, Singapore. In 2014, he decided to continue the work in Singapore by being installed as a full professor in applied biochemistry/biotechnology at the School of Biological Sciences[5] in the College of Science, Nanyang Technological University. Here he was heading a research group in drug discovery with emphasis on fragment screening and drug discovery.
After returning to Sweden in 2018 as a professor emeritus, he continued in 2021 research and teaching (bioentrepreneurship) at the Linköping University as appointed visiting professor[6] in the division of Cell- and Neurobiology, Department of Biomedicine and Clinical Sciences. His work there has been focused on the relevance of transient/weak/rapid/dynamic biological interactions and their applications in biosensors and drug discovery.
In 2017, Ohlson received the prestigious Affinity Award[7][8] on behalf of the International Society of Molecular Recognition (ISMR)[9] for outstanding contributions to the field of affinity technology. Ohlson is also named a Paul Harris Fellow from the Rotary Foundation of Rotary International.
Contributions to Science
[edit]Cell Culture Engineering
[edit]Ohlson has made significant contributions to the developments of whole-cell catalysts where intact microorganisms such as bacteria were harnessed by polymer networks for production of for example pharmaceutical substances such as steroid hormones.[10] By immobilization of enzymes and intact cells, processes can be performed in an efficient and economical way. This technique has been used in various industrial applications for large-scale production of valuable chemicals.
Ohlson demonstrated further that a lysate of platelets could be a useful alternative to fetal bovine serum for growing animal cells.[11]
Affinity Chromatography
[edit]Affinity chromatography has traditionally been used as a purification technique for substances in crude mixtures by high affinity to a target immobilized on a support material. Ohlson made pioneering studies in the 1970s of this technology by introducing HP(L)AC or (High Performance (Liquid) Affinity Chromatography)[12] where microparticulate supports used for HPLC were introduced for mainly analytical affinity chromatography but also for purification purposes. This resulted in rapid and efficient affinity chromatography where analysis can be performed in minutes. An example of HP(L)AC is the monitoring of monoclonal antibodies in in cell culture media.[13]
In 1990, Ohlson made breakthrough studies of affinity chromatography where he for the first time showed that weak or transient readily reversible bio specific interaction with dissociation constants (Kds) in the range of mM to μM can be the basis for chromatographic separations.[14][15] This new area was named Weak Affinity Chromatography or WAC for short and has now found wide-spread applications in many fields of biological sciences including clinical diagnostics.[16][17]
Continuous Biosensors
[edit]In general, transient biological interactions are difficult to detect and characterize but for Surface Plasmon Resonance (SPR) Ohlson demonstrated that SPR techniques can be used favorably to quantitatively detect weak biological binding.[18] As a consequence of utilizing weak but specific interactions between a target and an analyte, Ohlson designed in a pioneering study a continuous biosensor based on SPR with immobilized weak monoclonal antibodies where the fluctuating concentrations of the antigen can be followed in real time without any interference of the system.[19]
Drug Discovery
[edit]Transient- or weak interactions (dissociation constant Kd > μM) are ubiquitous in biological systems and they are critical for many biological processes. Based on their dynamic nature, they allow regulation and control of cellular activities and enable the formation of complex biological structures as DNA and proteins. However, they are difficult to see and are often perceived as non-specific and irrelevant. Ohlson has discussed this area in a highly recognized debate article where he introduced the concept of transient binding drugs.[20]
One important application of WAC has been its introduction in screening of small fragment molecules for drug discovery.[21][22] Here WAC was integrated with mass spectrometry (MS) to realize the complete analysis within days of a fragment library or a complex biological sample.
References
[edit]- ^ Ohlson, Sten (1980). "Immobilized whole-cell catalysts : applied to steroid conversions and denitrification of water (part 1) ; HPLAC = High performance liquid affinity chromatography (part 2)". Thesis.
- ^ Freiburghaus, Christian; Ohlson, Sten; Nilsson, Inga Marie (1988-01-01), "[41] Extracorporeal systems for adsorption of antibodies in hemophilia A and B", Methods in Enzymology, Immobilized Enzymes and Cells Part D, 137, Academic Press: 458–466, doi:10.1016/0076-6879(88)37043-6, ISBN 978-0-12-182037-4, PMID 3374353, retrieved 2025-01-13
- ^ "HyClone". Cytiva. Retrieved 2025-01-13.
- ^ "Linnaeus University", Wikipedia, 2024-12-27, retrieved 2025-01-14
- ^ "School of Biological Sciences (SBS)". School of Biological Sciences. Retrieved 2025-01-13.
- ^ "Sten Ohlson". liu.se. Retrieved 2025-01-13.
- ^ "Affinity Awards". ISMR. Retrieved 2025-01-13.
- ^ "Sten Ohlson fick pris vid konferens i Paris". Lnu.se (in Swedish). 2017-08-24. Retrieved 2025-01-14.
- ^ "ISMR". ISMR. Retrieved 2025-01-13.
- ^ Larsson, P. O.; Ohlson, S.; Mosbach, K. (1976-10-01). "New approach to steroid conversion using activated immobilised microorganisms". Nature. 263 (5580): 796–797. Bibcode:1976Natur.263..796L. doi:10.1038/263796a0. ISSN 1476-4687. PMID 995196.
- ^ Johansson, Liselott; Klinth, Jeanna; Holmqvist, Olov; Ohlson, Sten (2003-07-01). "Platelet lysate: a replacement for fetal bovine serum in animal cell culture?". Cytotechnology. 42 (2): 67–74. doi:10.1023/B:CYTO.0000009820.72920.cf. ISSN 1573-0778. PMC 3449796. PMID 19002929.
- ^ Ohlson, Sten; Hansson, Lennart; Larsson, Per-Olof; Mosbach, Klaus (1978). "High performance liquid affinity chromatography (HPLAC) and its application to the separation of enzymes and antigens". FEBS Letters. 93 (1): 5–9. Bibcode:1978FEBSL..93....5O. doi:10.1016/0014-5793(78)80792-3. ISSN 1873-3468. PMID 212311.
- ^ Holmberg, Ann; Ohlson, Sten; Lundgren, Torgny (1991-01-01), Spier, R. E.; Griffiths, J. B.; Meignier, B. (eds.), "RAPID MONITORING OF MONOCLONAL ANTIBODIES IN CELL CULTURE MEDIA BY HIGH PERFORMANCE LIQUID AFFINITY CHROMATOGRAPHY (HPLAC)", Production of Biologicals from Animal Cells in Culture, Butterworth-Heinemann, pp. 594–596, ISBN 978-0-7506-1103-9, retrieved 2025-01-13
- ^ Zopf, D.; Ohlson, S. (1990-07-01). "Weak-affinity chromatography". Nature. 346 (6279): 87–88. Bibcode:1990Natur.346...87Z. doi:10.1038/346087a0. ISSN 1476-4687.
- ^ Ohlson, Sten; Duong-Thi, Minh-Dao (2017), "Weak Affinity Chromatography (WAC)", Applied Biophysics for Drug Discovery, John Wiley & Sons, Ltd, pp. 107–130, doi:10.1002/9781119099512.ch7, ISBN 978-1-119-09951-2, retrieved 2025-01-13
- ^ Ohlson, Sten; Kaur, Jagjit; Raida, Manfred; Niss, Ulf; Bengala, Tim; Drum, Chester Lee; Boehm, Bernhard; Torres, Anthony R. (2017-09-01). "Direct analysis – no sample preparation – of bioavailable cortisol in human plasma by weak affinity chromatography (WAC)". Journal of Chromatography B. 1061–1062: 438–444. doi:10.1016/j.jchromb.2017.07.035. ISSN 1570-0232. PMID 28820982.
- ^ "Affinity chromatography", Wikipedia, 2024-06-24, retrieved 2025-01-14
- ^ Ohlson, Sten; Strandh, Magnus; Nilshans, Helena (1997). "Detection and characterization of weak affinity antibody antigen recognition with biomolecular interaction analysis". Journal of Molecular Recognition. 10 (3): 135–138. doi:10.1002/(SICI)1099-1352(199705/06)10:3<135::AID-JMR355>3.0.CO;2-B. ISSN 1099-1352. PMID 9408829.
- ^ Ohlson, Sten; Jungar, Christina; Strandh, Magnus; Mandenius, Carl-Fredrik (2000-02-01). "Continuous weak-affinity immunosensing". Trends in Biotechnology. 18 (2): 49–52. doi:10.1016/S0167-7799(99)01411-0. ISSN 0167-7799. PMID 10652508.
- ^ Ohlson, Sten (2008-05-01). "Designing transient binding drugs: A new concept for drug discovery". Drug Discovery Today. 13 (9): 433–439. doi:10.1016/j.drudis.2008.02.001. ISSN 1359-6446. PMID 18468561.
- ^ Duong-Thi, Minh-Dao; Meiby, Elinor; Bergström, Maria; Fex, Tomas; Isaksson, Roland; Ohlson, Sten (2011-07-01). "Weak affinity chromatography as a new approach for fragment screening in drug discovery". Analytical Biochemistry. 414 (1): 138–146. doi:10.1016/j.ab.2011.02.022. ISSN 0003-2697. PMID 21352794.
- ^ Ohlson, Sten; Duong-Thi, Minh-Dao (2018-08-15). "Fragment screening for drug leads by weak affinity chromatography (WAC-MS)". Methods. Affinity-Based Separation Methods for the Study of Biological Interactions. 146: 26–38. doi:10.1016/j.ymeth.2018.01.011. ISSN 1046-2023. PMID 29378316.